Astute Medical has revealed its first product candidate, the NephroCheck test, at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels, Belgium. The test, which will be launched in Europe later in 2012, is intended to aid in the risk assessment for acute kidney injury (AKI) in critically ill patients, a condition with mortality rates approaching 40 to 80 per cent for severely ill patients in intensive care settings (ICU).
The NephroCheck test employs immunoassay technology to identify changes in biomarker measurements that correlate with risk for AKI. The test is performed on a small cartridge that employs microfludic engineering to conduct most sample processing steps. Biomarker measurements are read by the Astute140 meter, which delivers results in around 20 minutes. Astute used its research platform to identify and testbiomarkers used in the NephroCheck test. After assessing target candidates, researchers performed a series of studies to identify the most promising biomarker targets.